Compare Enveric Biosciences Inc (ENVB) vs State Street Technology Select Sector SPDR ETF (XLK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs State Street Technology Select Sector SPDR ETF — how do they compare? Enveric Biosciences Inc trades at $1.56 (market cap $6.20M), while State Street Technology Select Sector SPDR ETF trades at $188.48. The key difference: State Street Technology Select Sector SPDR ETF is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals.
| ENVB | XLK | |
|---|---|---|
Market Cap | $6.20M | — |
Sector | Health | Sector/Thematic |
52-Week High | $17.40 | $198.21 |
52-Week Low | $1.27 | $127.49 |
Enterprise Value | $1.30M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.55, up 0.65% with a bullish technical signal. The company shows negative profitability metrics with ROE at -257.95% and ROA at -218.01% for 2025, but has consistently beaten earnings expectations. Recent news highlights positive preclinical data for EB-003 and FDA guidance support for psychedelic drug development. Cash flow remains challenging with negative operational cash flow offset by financing activities.
Despite negative profitability, ENVB's consistent earnings beats and strong analyst support (75% buy rating) suggest potential upside. Key risks include ongoing cash burn and regulatory hurdles in drug development. The stock's technical strength and positive clinical developments provide catalysts, but investors should monitor cash position and regulatory progress closely.
XLK trades at $188.86, up 1.36% with a bullish technical signal from moving averages. The ETF shows strong momentum near resistance at $189, supported by sector inflows and earnings growth. Recent news highlights tech sector leadership and investor accumulation during selloffs, though concentration risk remains a concern.
Outlook is positive with tech earnings driving gains, but overbought RSI and high dependence on mega-caps pose near-term risks. Long-term growth hinges on AI adoption and sector diversification, with analysts favoring broad tech exposure alternatives for valuation advantages.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About State Street Technology Select Sector SPDR ETF
XLK tracks the Technology Select Sector Index, providing targeted exposure to the largest and most influential technology companies within the S&P 500. It is a highly concentrated, liquid vehicle focused on software, semiconductors, and hardware leaders, serving as the primary benchmark for U.S. large-cap technology performance.
Read more on XLK →
